| Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients T Iwase, T Sangai, T Nagashima, M Sakakibara, J Sakakibara, S Hayama, ... Cancer medicine 5 (1), 41-48, 2016 | 93 | 2016 |
| Body composition and breast cancer risk and treatment: mechanisms and impact T Iwase, X Wang, TV Shrimanker, MG Kolonin, NT Ueno Breast cancer research and treatment 186, 273-283, 2021 | 73 | 2021 |
| An increased neutrophil-to-lymphocyte ratio predicts poorer survival following recurrence for patients with breast cancer T Iwase, T Sangai, M Sakakibara, J Sakakibara, E Ishigami, S Hayama, ... Molecular and Clinical Oncology 6 (2), 266-270, 2017 | 47 | 2017 |
| Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer T Iwase, T Sangai, H Fujimoto, Y Sawabe, K Matsushita, K Nagashima, ... Breast cancer research and treatment 179, 435-443, 2020 | 37 | 2020 |
| Targeting signaling pathways in inflammatory breast cancer X Wang, T Semba, LTH Phi, S Chainitikun, T Iwase, B Lim, NT Ueno Cancers 12 (9), 2479, 2020 | 29 | 2020 |
| Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer NT Ueno, RK Tahara, T Fujii, JM Reuben, H Gao, B Saigal, A Lucci, ... Cancer medicine 9 (3), 1025-1032, 2020 | 26 | 2020 |
| A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment B Lim, RK Murthy, J Lee, SA Jackson, T Iwase, DW Davis, JS Willey, J Wu, ... British journal of cancer 120 (12), 1105-1112, 2019 | 24 | 2019 |
| The effect of molecular subtype and body mass index on neo-adjuvant chemotherapy in breast cancer patients T Iwase, R Nakamura, N Yamamoto, A Yoshi, M Itami, M Miyazaki The breast 23 (3), 264-272, 2014 | 21 | 2014 |
| A novel immunomodulatory 27-gene signature to predict response to neoadjuvant immunochemotherapy for primary triple-negative breast cancer T Iwase, KRM Blenman, X Li, E Reisenbichler, R Seitz, D Hout, TJ Nielsen, ... Cancers 13 (19), 4839, 2021 | 20 | 2021 |
| EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer X Wang, T Semba, GC Manyam, J Wang, S Shao, F Bertucci, P Finetti, ... Science Advances 8 (50), eabn7983, 2022 | 17 | 2022 |
| The relationship between skeletal-related events and bone scan index for the treatment of bone metastasis with breast cancer patients T Iwase, N Yamamoto, H Ichihara, T Togawa, T Nagashima, M Miyazaki Medicine 93 (28), e269, 2014 | 17 | 2014 |
| Volumetric breast density is essential for predicting cosmetic outcome at the late stage after breast-conserving surgery N Shiina, M Sakakibara, K Fujisaki, T Iwase, T Nagashima, T Sangai, ... European Journal of Surgical Oncology (EJSO) 42 (4), 481-488, 2016 | 15 | 2016 |
| Changes in overall survival over time for patients with de novo metastatic breast cancer T Iwase, TV Shrimanker, R Rodriguez-Bautista, O Sahin, A James, J Wu, ... Cancers 13 (11), 2650, 2021 | 13 | 2021 |
| PI3K and MAPK pathways as targets for combination with the pan-HER irreversible inhibitor Neratinib in HER2-positive breast cancer and TNBC by kinome RNAi screening J Lee, H Liu, T Pearson, T Iwase, J Fuson, AS Lalani, LD Eli, I Diala, ... Biomedicines 9 (7), 740, 2021 | 11 | 2021 |
| Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes T Kogawa, T Fujii, TM Fouad, DD Liu, K Harano, H Masuda, T Iwase, ... Breast cancer research and treatment 171, 501-511, 2018 | 11 | 2018 |
| Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review S Chainitikun, JR Espinosa Fernandez, JP Long, T Iwase, K Kida, X Wang, ... Plos one 16 (4), e0250057, 2021 | 6 | 2021 |
| The prognostic impact of body composition for locally advanced breast cancer patients who received neoadjuvant chemotherapy T Iwase, A Parikh, SS Dibaj, Y Shen, TV Shrimanker, S Chainitikun, ... Cancers 13 (4), 608, 2021 | 6 | 2021 |
| Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC T Iwase, K Harano, H Masuda, K Kida, KR Hess, Y Wang, L Dirix, ... BMC cancer 20, 1-9, 2020 | 5 | 2020 |
| Advanced small-cell colon carcinoma: a case report T Iwase, Y Masuda, T Suzuki, O Takahashi, M Miyazaki Journal of Medical Case Reports 7, 1-4, 2013 | 5 | 2013 |
| The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer S Chainitikun, JP Long, R Rodriguez-Bautista, T Iwase, D Tripathy, T Fujii, ... Breast cancer research and treatment 183, 729-739, 2020 | 4 | 2020 |
Naoto T UenoUniversity of Hawaiʻi Cancer CenterVerified email at cc.hawaii.edu
